Cargando…
Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
Autores principales: | Lai, Fangfang, Ji, Ming, Huang, Lei, Wang, Yunchen, Xue, Nina, Du, Tingting, Dong, Kai, Yao, Xiaoqing, Jin, Jing, Feng, Zhiqiang, Chen, Xiaoguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372818/ https://www.ncbi.nlm.nih.gov/pubmed/37521865 http://dx.doi.org/10.1016/j.apsb.2023.05.003 |
Ejemplares similares
-
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
por: Lai, Fangfang, et al.
Publicado: (2022) -
Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
por: Li, Guangdi, et al.
Publicado: (2023) -
Strain driven emergence of topological non-triviality in YPdBi thin films
por: Bhardwaj, Vishal, et al.
Publicado: (2021) -
Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]
por: Wu, Canhao, et al.
Publicado: (2023) -
Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies
por: Jiang, Jianwei, et al.
Publicado: (2021)